Physician profile
Gary Alweiss
NPI 1609838986
$13,181.47
in general payments reported to CMS, 2019-2025
62 companies · $2,652 in 2025
The $2,652 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $1,439 · 2021: $1,307 · 2022: $2,024 · 2023: $2,518 · 2024: $2,211 · 2025: $2,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,198 · Consulting Fee: $150 · Education: $34.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,197.62 |
| Consulting Fee | $150.00 |
| Education | $34.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $3,521.20 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Abbvie INC. | $757.64 | 2019-2025 | Duopa, Qulipta, Botox |
| Emd Serono, INC. | $686.71 | 2019-2024 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $518.30 | 2019-2025 | |
| Biogen, INC. | $480.60 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Celgene Corporation | $473.75 | 2021-2025 | Zeposia |
| Lilly USA, LLC | $460.67 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Amgen INC. | $409.64 | 2019-2025 | Uplizna |
| Pfizer INC. | $406.57 | 2021-2025 | |
| Allergan, INC. | $388.55 | 2019-2021 | |
| Csl Behring | $370.85 | 2020-2025 | Hizentra |
| Eisai INC. | $365.89 | 2023-2025 | |
| Argenx US, INC. | $354.40 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $316.56 | 2019-2025 | Ultomiris |
| Lundbeck LLC | $295.25 | 2019-2025 | Vyepti, Rexulti |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Alweiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.